How Do Experience And Capacity Impact Small Molecule API Outsourcing?

In Q2 2018, ISR asked 60 outsourcers of small molecule drug substance manufacturing to select from four different reasons that manufacturing may be split between in-house and external resources. The data below show how respondents rated their organization’s experience and capacity with respect to outsourcing manufacturing of the active pharmaceutical ingredients. Interestingly, one-quarter of respondents (24%) stated their company lacks both capacity and experience to manufacture drug substance. To learn more, follow the link to the Development and Commercial Manufacturing Outsourcing Models report preview.